General Info

NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. The company s platform nanotechnology is based on materials that on conversion to nanoscale exhibit different physical properties from bulk silver or other noble metals. NUCRYST is also researching potential pharmaceutical products containing NPI 32101 for use in the treatment of gastrointestinal disorders. It is also exploring its use to treat inflammatory bowel disease, including ulcerative colitis and Crohn s disease. The company s business strategy is to maximize return on investment by partnering with established pharmaceutical market leaders for effective market penetration of its businesses either through out-licensing or co-development and co-marketing agreements. NUCRYST Pharmaceuticals is headquartered in Wakefield, Mass., and operates a manufacturing facility in Fort Saskatchewan, Alberta.